TXNRD1 and cancer: As an example, Saei and collaborators developed a comprehensive chemical proteomics profiling approach for target deconvolution of a redox active drug auranofin (originally and anti-rheumatic called Ridaura) as an anti-cancer drug auranofin was found to target genes such as TXNRD1, NFKB2, and CHORDC1, all of them known to be involved in the perturbation of oxidoreductase pathways in cancer (181).